108 related articles for article (PubMed ID: 10996000)
21. A large-scale method for T cell depletion: towards graft engineering of mobilized peripheral blood stem cells.
Gordon PR; Leimig T; Mueller I; Babarin-Dorner A; Holladay MA; Houston J; Kerst G; Geiger T; Handgretinger R
Bone Marrow Transplant; 2002 Jul; 30(2):69-74. PubMed ID: 12132044
[TBL] [Abstract][Full Text] [Related]
22. Selective Depletion of αβ T Cells and B Cells for Human Leukocyte Antigen-Haploidentical Hematopoietic Stem Cell Transplantation. A Three-Year Follow-Up of Procedure Efficiency.
Li Pira G; Malaspina D; Girolami E; Biagini S; Cicchetti E; Conflitti G; Broglia M; Ceccarelli S; Lazzaro S; Pagliara D; Meschini A; Bertaina A; Montanari M; Locatelli F
Biol Blood Marrow Transplant; 2016 Nov; 22(11):2056-2064. PubMed ID: 27519279
[TBL] [Abstract][Full Text] [Related]
23. T cells recognizing leukemic CD34(+) progenitor cells mediate the antileukemic effect of donor lymphocyte infusions for relapsed chronic myeloid leukemia after allogeneic stem cell transplantation.
Smit WM; Rijnbeek M; van Bergen CA; Fibbe WE; Willemze R; Falkenburg JH
Proc Natl Acad Sci U S A; 1998 Aug; 95(17):10152-7. PubMed ID: 9707616
[TBL] [Abstract][Full Text] [Related]
24. Successful autologous stem cell collection in patients with chronic myeloid leukemia in complete cytogenetic response, with quantitative measurement of BCR-ABL expression in blood, marrow, and apheresis products.
Gordon MK; Sher D; Karrison T; Kebriaei P; Chuang K; Zhang Y; McDonnell D; Artz A; Godley L; Odenike O; Rich E; Michaelis L; Thirman MJ; Wickrema A; van Besien K; Larson RA; Stock W
Leuk Lymphoma; 2008 Mar; 49(3):531-7. PubMed ID: 18297531
[TBL] [Abstract][Full Text] [Related]
25. Clinical outcomes and graft characteristics in pediatric hematopoietic stem cell transplantation: Effect of granulocyte-colony stimulating factor priming.
Fettah A; Özbek N; Azık F; Tavil B; Özgüner M; Avcı Z; Işık P; Yaralı N; Uçkan D; Tunç B
Transfus Apher Sci; 2015 Jun; 52(3):332-8. PubMed ID: 25779226
[TBL] [Abstract][Full Text] [Related]
26. Peripheral blood progenitor cell mobilization with intermediate-dose cyclophosphamide, sequential granulocyte-macrophage-colony-stimulating factor and granulocyte-colony-stimulating factor, and scheduled commencement of leukapheresis in 225 patients undergoing autologous transplantation.
Bashey A; Donohue M; Liu L; Medina B; Corringham S; Ihasz A; Carrier E; Castro JE; Holman PR; Xu R; Law P; Ball ED; Lane TA
Transfusion; 2007 Nov; 47(11):2153-60. PubMed ID: 17958545
[TBL] [Abstract][Full Text] [Related]
27. Single leukapheresis products collected from healthy donors after the administration of granulocyte colony-stimulating factor contain ten-fold higher numbers of long-term reconstituting hematopoietic progenitor cells than conventional bone marrow allografts.
Theilgaard-Mönch K; Raaschou-Jensen K; Andersen H; Russell CA; Vindeløv L; Jacobsen N; Dickmeiss E
Bone Marrow Transplant; 1999 Feb; 23(3):243-9. PubMed ID: 10084255
[TBL] [Abstract][Full Text] [Related]
28. Not all healthy donors mobilize hematopoietic progenitor cells sufficiently after G-CSF administration to allow for subsequent CD34 purification of the leukapheresis product.
Holm M
J Hematother; 1998 Apr; 7(2):111-3. PubMed ID: 9597568
[No Abstract] [Full Text] [Related]
29. [Collection of hematopoietic progenitor cells from healthy donors].
Bojanić I; Cepulić BG; Mazić S
Acta Med Croatica; 2009 Jun; 63(3):237-44. PubMed ID: 19827352
[TBL] [Abstract][Full Text] [Related]
30. Pegylated granulocyte colony-stimulating factor mobilizes CD34+ cells with different stem and progenitor subsets and distinct functional properties in comparison with unconjugated granulocyte colony-stimulating factor.
Bruns I; Steidl U; Fischer JC; Czibere A; Kobbe G; Raschke S; Singh R; Fenk R; Rosskopf M; Pechtel S; von Haeseler A; Wernet P; Tenen DG; Haas R; Kronenwett R
Haematologica; 2008 Mar; 93(3):347-55. PubMed ID: 18268278
[TBL] [Abstract][Full Text] [Related]
31. High-dose hydroxyurea plus G-CSF mobilize BCR-ABL-negative progenitor cells (CFC, LTC-IC) into the blood of newly diagnosed CML patients at any time of hematopoietic regeneration.
Petzer AL; Hochenburger E; Haun M; Duba HCh; Grünewald K; Hoflehner E; Sill H; Linkesch W; Gastl G; Gunsilius E
J Hematother Stem Cell Res; 2002 Apr; 11(2):293-300. PubMed ID: 11983100
[TBL] [Abstract][Full Text] [Related]
32. Mobilization and selection of peripheral blood hematopoietic progenitors in children with systemic sclerosis.
Locatelli F; Perotti C; Torretta L; Maccario R; Montagna D; Ravelli A; Giorgiani G; De Benedetti F; Giraldi E; Magnani ML; De Stefano P; Martini A
Haematologica; 1999 Sep; 84(9):839-43. PubMed ID: 10477459
[TBL] [Abstract][Full Text] [Related]
33. Successful mobilization of Ph-negative blood stem cells with intensive chemotherapy + G-CSF in patients with chronic myelogenous leukemia in first chronic phase.
Olsson-Strömberg U; Höglund M; Björkholm M; Braide I; Carlson K; Gahrton G; Grimfors G; Hast R; Lerner R; Linder O; Ljungman P; Löfvenberg E; Malm C; Nilsson PG; Paul C; Rödjer S; Stenke L; Tidefeldt U; Turesson I; Uden AM; Wahlin A; Vilen L; Winqvist I; Zettervall O; Oberg G; Simonsson B
Leuk Lymphoma; 2006 Sep; 47(9):1768-73. PubMed ID: 17064986
[TBL] [Abstract][Full Text] [Related]
34. Collection of Ph-negative progenitor cells from Ph+ CML patients in complete cytogenetic remission after long-term interferon-alpha therapy.
Russo D; Martinelli G; Montefusco V; Amabile M; Rosti G; Marin L
Haematologica; 1999 Oct; 84(10):953-5. PubMed ID: 10509048
[No Abstract] [Full Text] [Related]
35. Dendritic cell-based vaccines in the setting of peripheral blood stem cell transplantation: CD34+ cell-depleted mobilized peripheral blood can serve as a source of potent dendritic cells.
Choi D; Perrin M; Hoffmann S; Chang AE; Ratanatharathorn V; Uberti J; McDonagh KT; Mulé JJ
Clin Cancer Res; 1998 Nov; 4(11):2709-16. PubMed ID: 9829733
[TBL] [Abstract][Full Text] [Related]
36. Long-term immune reconstitution after anti-CD52-treated or anti-CD34-treated hematopoietic stem cell transplantation for severe T-lymphocyte immunodeficiency.
Slatter MA; Brigham K; Dickinson AM; Harvey HL; Barge D; Jackson A; Bown N; Flood TJ; Cant AJ; Abinun M; Gennery AR
J Allergy Clin Immunol; 2008 Feb; 121(2):361-7. PubMed ID: 18086494
[TBL] [Abstract][Full Text] [Related]
37. Isolation of purified autologous peripheral blood CD34+ cells with low T cell content using CliniMACS device--a local experience.
Leong CF; Habsah A; Teh HS; Goh KY; Fadilah SA; Cheong SK
Malays J Pathol; 2008 Jun; 30(1):31-6. PubMed ID: 19108409
[TBL] [Abstract][Full Text] [Related]
38. Collection of Ph-negative progenitor cells from interferon responsive patients with chronic myeloid leukemia: effect of granulocyte-colony-stimulating factor mobilization.
Olavarria E; Parker S; Craddock C; Philpott N; Tiniakou M; Chase A; Kanfer E; Apperley JF; Goldman JM
Haematologica; 2000 Jun; 85(6):647-52. PubMed ID: 10870123
[TBL] [Abstract][Full Text] [Related]
39. The impact of granulocyte colony stimulating factor at content of donor lymphocytes collected for cellular immunotherapy.
Arat M; Arslan O; Gürman G; Dalva K; Ozcan M; Uğur A; Ilhan O
Transfus Apher Sci; 2004 Feb; 30(1):9-15. PubMed ID: 14746816
[TBL] [Abstract][Full Text] [Related]
40. Highly effective CD34+ selection of granulocyte colony-stimulating factor-mobilized allogeneic peripheral blood progenitor cells.
Schreiner T; Maccari B; Erne E; Bischof C; Wiesneth M
Blood; 1996 Aug; 88(4):1517-8. PubMed ID: 8695877
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
